Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. (CMMB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cmmb · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Chemomab Therapeutics Ltd. (CMMB) measures how much investors pay for each dollar of the company's trailing earnings. CMMB's current PE ratio of N/A is calculated by dividing its stock price of $1.81 by its TTM earnings per share of -$0.93.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2008 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Chemomab Therapeutics Ltd.You CMMB | $11M | N/A | — | -$0.93 |
 BioVie Inc. BIVI | $13M | N/A | — | -$11.87 |
 Can-Fite BioPharma Ltd. CANF | $2M | N/A | — | -$12.02 |
 CERo Therapeutics Holdings, Inc. CERO | $0M | N/A | — | -$4.71 |
 PMGC Holdings Inc. ELAB | $3M | N/A | — | -$378.74 |
 Galmed Pharmaceuticals Ltd. GLMD | $3M | N/A | — | -$2.39 |
 InMed Pharmaceuticals Inc. INM | $3M | N/A | — | -$8.36 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.41 | — | |
2024-12-31 FY2024 | — | $-3.11 | — | |
2023-12-31 FY2023 | — | $-8.25 | — | |
2022-12-31 FY2022 | — | $-9.72 | — | |
2021-12-31 FY2021 | — | $-4.81 | — | |
2020-12-31 FY2020 | — | $-12.83 | — | |
2019-12-31 FY2019 | — | $-63.20 | — | |
2018-12-31 FY2018 | — | $-87.37 | — | |
2017-12-31 FY2017 | — | $-869.25 | — | |
2016-12-31 FY2016 | — | $-69.69 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Chemomab Therapeutics Ltd. (CMMB) measures how much investors pay for each dollar of the company's trailing earnings. CMMB's current PE ratio of N/A is calculated by dividing its stock price of $1.81 by its TTM earnings per share of -$0.93.
Frequently asked questions
CMMB pe ratio · 6 questionsCMMB's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.81 and TTM EPS of -$0.93. Data sourced from Financial Modeling Prep via CMMB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Chemomab Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09